Elysia 4-2A

Solution dedicated to quality control in laboratories for the production of Radio Pharmaceuticals (equipment / SW / services).

Equity

€9,600

total amount raised in round

Campaign Closed

In the context of a new capital increase of EUR 400,000, at a price of EUR 400 per share, we are offering Elysia's historical investors the possibility to exercise their preferential right and reinvest in the company for a maximum amount of EUR 23,600 (representing 59 shares) and this until Tuesday, July 30th, 2019.

Following an agreement, the early stage venture capital fund, Inventures I, will retrocede a part of its shares to Spreds Finance. More precisely, Inventures I already invested in Elysia SA/NV for an amount of EUR 100,000 and will retrocede shares for an amount of maximum EUR 23,600 to Spreds Finance.

Please note that given the fact that this is a share purchase deal, the tax shelter benefit will not be available.